Australia Noninvasive Prenatal Testing Market Size, Share, Growth and Forecast, 2025-2035

Older mothers and funded RhD tests widen cfDNA screening

The Australia noninvasive prenatal testing market was valued at USD 59.5 million in 2025 and is projected to increase from USD 70.0 million in 2026 to USD 136.9 million by 2035, registering a CAGR of 7.74% during 2026–2035. Demand comes from older mothers who seek the most accurate first-trimester screen, from obstetricians and general practitioners who now offer cell-free DNA screening ahead of serum-based risk scores, and from a Medicare-funded pathway that predicts fetal RhD status for RhD-negative women. New South Wales held the largest share, 40.2% in 2025, because the state records the most births and hosts large private pathology laboratories. Remaining states and territories form the fastest-growing group at 8.60% a year, as public laboratories in Western Australia add funded RhD testing for local patients. Most chromosome screens remain self-funded, so price, turnaround and bundled genetic counseling decide which laboratory wins each referral.

Which cell-free DNA pregnancy tests does the estimate count?

The estimate counts spending on laboratory tests that analyze cell-free fetal DNA in a pregnant woman's blood to screen for chromosome conditions, predict fetal blood group or assess single-gene conditions in Australia. It includes self-paid chromosome screens, Medicare-billed fetal RhD tests and work performed under hospital or state contracts, whether processed in Australian or overseas laboratories.

The estimate excludes maternal serum screening, nuchal translucency scans, amniocentesis, chorionic villus sampling and newborn screening, as well as the sale of sequencers and reagents to laboratories. The value chain runs from collection centers and fertility clinics through accredited genetics laboratories to the obstetricians, midwives and general practitioners who request the test and explain results.

Aneuploidy screens lead while fetal RhD tests grow fastest

Why does common aneuploidy screening hold the largest share?

Based on application, the market is categorized into Common aneuploidy screening, Expanded chromosomal screening, Fetal blood group testing and Monogenic prenatal testing. Common aneuploidy screening led with a 63.0% share of 2025 value, because screens for trisomy 21, 18 and 13 are the standard self-paid test. Fetal blood group testing grows fastest at 9.82% a year, as Medicare-funded RhD prediction reaches more RhD-negative women.

Which laboratory methods dominate cell-free DNA screening?

Based on technology, the market is categorized into Chromosome-counting sequencing, Targeted chromosomal assays and Fetal genotyping assays. Chromosome-counting sequencing led with a 68.0% share of 2025 value, because most Australian laboratories run whole-genome counting methods that also support genome-wide options. Fetal genotyping assays grow fastest at 9.23% a year, as quantitative PCR methods for fetal RHD spread from one national service to public and private laboratories.

How do pregnancy risk groups shape test volumes?

Based on customer type, the market is categorized into Routine-risk pregnancies, Elevated-risk pregnancies and RhD-negative pregnancies. Routine-risk pregnancies led with a 64.0% share of 2025 value, because clinicians now offer cell-free DNA screening as a first-line option rather than only after a high serum risk score. RhD-negative pregnancies grow fastest at 9.29% a year, as national guidance supports fetal RHD testing for every RhD-negative woman.

Who pays for cell-free DNA screening in Australia?

Based on revenue model, the market is categorized into Patient self-pay, Medicare-funded and Institutional contracts. Patient self-pay led with 80.0% of 2025 value, because chromosome screens carry no Medicare rebate and patients pay the laboratory directly. Medicare-funded work grows fastest at 9.64% a year, as more RhD tests are billed to Medicare and a wider subsidy remains under debate alongside reproductive carrier screening items.

Maternal age, serum test substitution and RhD funding

Why do older mothers keep screening demand rising?

Australian mothers are having children later, and the chance of a chromosome condition rises with maternal age, which keeps demand for the most sensitive screen high. The Australian Bureau of Statistics reported a median maternal age of 32.1 years for births registered in 2024, with 292,318 births in total. The ABS Births, Australia, 2024 publication showed fertility rates for women aged 30 to 49 rising while rates for women under 30 declined. Women aged 35 to 39 recorded 66.6 births per 1,000 women in 2024, up from 65.5 a year earlier. As a result, Common aneuploidy screening keeps 63.0% of 2025 value, while older first-time mothers often add genome-wide options.

How is cell-free DNA screening displacing serum-based risk scores?

Clinicians and patients increasingly choose cell-free DNA screening as the primary test instead of the combined first-trimester serum and ultrasound screen, which shifts spending toward laboratories that run it. A population study of Victoria published in Genetics in Medicine found that combined first-trimester screening uptake fell from 77.5% in 2013 to 68.1% in 2015 as the newer test spread. The same study recorded a 39.6% drop in invasive diagnostic procedures between 2012 and 2015. Pregnancy, Birth and Baby, the federal information service, states that the test detects more than 99% of Down syndrome cases from about 10 weeks. Consequently, Routine-risk pregnancies hold 64.0% of 2025 value as first-line screening spreads.

Download Free Sample

How does Medicare funding widen fetal RhD testing?

A funded pathway now lets RhD-negative women learn the fetal blood group before receiving anti-D, which turns a niche reference test into a routine pregnancy service. Medicare items for fetal RHD testing have been available since July 2022, and the Medical Services Advisory Committee supported raising the fee for item 73420 from A$56.00 to A$150.40, with modeled volumes above 51,000 services a year. The Australian and New Zealand Society of Blood Transfusion estimates about 45,000 RhD-negative women give birth each year. Australian Red Cross Lifeblood then began Medicare-billed testing on May 28, 2025. As a result, RhD-negative pregnancies grow fastest at 9.29% a year.

Why do genome-wide options raise spending per test?

Laboratories are adding genome-wide and microdeletion options to the standard trisomy screen, which raises the average value of each request. Sonic Genetics offers genome-wide screening for an additional charge, while Genomic Diagnostics lists its Generation test at A$485, Generation 46 at A$525 and Generation Plus at A$799 as of August 2025. Victorian Clinical Genetics Services prices its percept test, which reviews all 23 chromosome pairs, at A$475. Monash IVF also markets a genome-wide nest+ option alongside its standard nest test. In turn, Expanded chromosomal screening and wider chromosome reviews lift revenue even when birth numbers stay flat.

Domestic labs, public RhD services and subsidy openings

Why is the shift to domestic sequencing laboratories accelerating?

Chromosome screening has shifted from overseas send-out models to Australian laboratories that offer faster results and local data handling. Sonic Genetics has provided the test since 2013, brought it into its Australian laboratories in 2015 and now runs it in 2 accredited sites. Australian Clinical Labs processes its Harmony screen in its own genetics laboratory, with results reaching the doctor in 5 to 10 business days. Victorian Clinical Genetics Services returns percept results 3 to 5 working days after receipt using massively parallel sequencing. However, Genomic Diagnostics still sends its Generation Plus test to an accredited laboratory in California. As a result, Chromosome-counting sequencing keeps 68.0% of 2025 value.

How are public RhD testing services changing supply?

Fetal RHD testing is moving from a single reference laboratory into public pathology services in several states, which widens access for RhD-negative women. PathWest began a pilot at King Edward Memorial Hospital in October 2023 and opened RhD screening to Medicare-eligible patients on Nov. 4, 2024. Lifeblood now processes samples collected after 15 weeks at its Brisbane center, with referring laboratories arranging refrigerated transport within 72 hours. Western Australia and New South Wales had both decided to set up public-provider testing, according to a February 2024 report for the Australian Government. Consequently, the smaller states and territories gain funded capacity, which also supports demand for blood group typing services.

Download Free Sample

Could a Medicare subsidy unlock wider screening uptake?

A public subsidy for chromosome screening would open the test to families who now skip it because of cost. A survey of health professionals led by Monash University and reported by newsGP on June 17, 2024, found that 94.1% named out-of-pocket costs as the main barrier. Patients typically pay about A$400 to A$500 because the test carries no Medicare rebate. The researchers recommended a Medicare subsidy, noting that carrier testing for cystic fibrosis, spinal muscular atrophy and fragile X gained an item in November 2023. Even without that subsidy, Medicare-funded work grows fastest at 9.64% a year as billed RhD testing volumes rise.

Can fertility clinic referrals open a higher-value channel?

Fertility clinics see patients who are older, already counseled on genetics and willing to pay for broader screening, which makes them an attractive referral channel. Monash IVF performs its nest test at its own clinics and specialist women's ultrasound centers across Australia and includes genetic counseling at no extra cost. Victorian Clinical Genetics Services markets percept for donor egg or sperm pregnancies, twins and triplets, while Australian Clinical Labs accepts IVF singleton and twin pregnancies, including egg donor cases. Many of these patients already use next-generation sequencing panels before conception, and the ABS counted 4,191 multiple-birth pregnancies in 2024. Monash IVF also offers its screen from 10 weeks of pregnancy. As a result, Expanded chromosomal screening gains from fertility clinic referrals that combine several genetic tests.

Out-of-pocket fees, fewer births and thin RhD rebates

How do out-of-pocket fees limit equitable access?

Chromosome screens remain self-funded, so lower-income families are less likely to use them. Pregnancy, Birth and Baby states that the test is not covered by Medicare or private health insurance. As a result, uptake depends on household budgets and on whether clinicians raise the option during short consultations. Laboratories respond with bundled counseling, flat pricing and tiered options that keep the basic screen near A$450.

Why does a falling birth rate cap volume growth?

Fewer births per woman limit how many pregnancies can be screened each year. Australia's total fertility rate fell to 1.481 births per woman in 2024 from 1.855 in 2013, according to the World Bank. As a result, volume growth now depends on higher uptake per pregnancy rather than more pregnancies. Laboratories offset this by selling genome-wide options and by adding funded RhD testing.

Why have thin RhD rebates slowed commercial rollout?

The original A$56 rebate for fetal RHD testing was too low to attract most commercial laboratories. A February 2024 report for the Australian Government described the rebate as considerably underfunded and noted that no TGA-registered RHD kits were approved. As a result, only a few public and national services offered the test at first. The higher fee from Nov. 1, 2024, improves the economics for new entrants.

How do accuracy limits of expanded screens affect demand?

Expanded screens find more conditions but carry lower accuracy than the core trisomy test, which complicates counseling. Sonic Genetics states that genome-wide accuracy is good but lower than for sex chromosome conditions, with limited data in twins. As a result, some clinicians hesitate to recommend expanded options for routine pregnancies. Laboratories respond with post-test genetic counseling and clear guidance on confirmatory diagnostic procedures.

New South Wales leads while smaller states grow fastest

Why does New South Wales hold the largest share?

New South Wales held 40.2% of 2025 value and grows at 7.50% a year, because it records the most births of any region and hosts large private genetics laboratories. The Australian Bureau of Statistics counted 86,978 registered births in New South Wales in 2024, the highest of any state. Sonic Genetics and Australian Clinical Labs both process chromosome screens in their own Australian laboratories. New South Wales also decided to set up public RhD testing, which adds a funded stream over the forecast period.

How do clinical genetics services shape Victoria?

Victoria held a 29.9% share of 2025 value and grows at 7.65% a year, supported by a strong clinical genetics base and older mothers. Victorian Clinical Genetics Services runs the percept genome-wide test with results in three to five working days. Victoria registered 82,328 births in 2024, and its median maternal age of 32.7 years was among the highest in Australia. Victorian data also first showed how cell-free DNA screening displaced the combined first-trimester screen after 2013.

Download Free Sample

What supports demand in Queensland?

Queensland held a 24.7% share of 2025 value and grows at 8.05% a year, as birth numbers hold steady and RhD testing expands. The state registered 58,986 births in 2024, up 0.7% from 2023. Lifeblood processes national RhD screening samples at its Brisbane center, and its red cell reference laboratory in Queensland also provides specialized analysis for sensitized women. As a result, clinicians in the region gain early access to funded fetal blood group testing.

Why do the smaller states and territories grow fastest?

Remaining states and territories held a 5.2% share of 2025 value and grow fastest at 8.60% a year, as public RhD services expand. PathWest opened RhD screening to Medicare-eligible patients in Western Australia in November 2024, after a pilot at King Edward Memorial Hospital. Western Australia registered 30,516 births and South Australia 18,516 in 2024. The Australian Capital Territory recorded the highest median maternal age at 32.8 years, which supports screening uptake.

Download Free Sample

RhD funding, public lab launches and new pricing, 2024–2025

Sequencing, targeted assays and fetal genotyping compared

• Chromosome-counting sequencing reads millions of DNA fragments to count each chromosome, and it supports the genome-wide options sold by Sonic Genetics and Victorian Clinical Genetics Services.
• Targeted chromosomal assays analyze selected regions of chromosomes 21, 18, 13, X and Y, which keeps the cost per sample lower for the core screen.
• Fetal genotyping assays use quantitative PCR on cell-free DNA to detect the RHD gene, and laboratories validate them alongside other in vitro diagnostics before Medicare billing.
• Genome-wide add-ons look for segmental gains and losses across all chromosomes, although accuracy is lower than for the common trisomies.

Private pathology, clinical genetics and public labs compete

Competition in Australian noninvasive prenatal testing splits between national private pathology groups, clinical genetics services and public laboratories that dominate funded RhD work. Sonic Genetics has offered the test since 2013 and runs it in two accredited Australian laboratories, with a genome-wide option. Australian Clinical Labs processes the Harmony screen in its own genetics laboratory, while Genomic Diagnostics sells its Generation range and sends Generation Plus to a partner laboratory in California. Victorian Clinical Genetics Services competes on turnaround with percept, and Monash IVF bundles nest with genetic counseling in its clinics. In the funded segment, Australian Red Cross Lifeblood and PathWest lead RhD screening. Laboratories compete on price, turnaround, counseling support and the breadth of genome-wide options.

Which laboratories lead cell-free DNA screening in Australia?

Credence Research view on cfDNA screening in Australia

Credence Research's view is that the Australia noninvasive prenatal testing market will grow steadily, because older mothers, clinician preference and funded RhD testing raise use per pregnancy even as births stay flat. Self-paid chromosome screens will keep most of the value, while fetal blood group testing adds the fastest growth as public and national services scale up. Genome-wide options also lift the average spending on each laboratory request. A Medicare subsidy for chromosome screening would be the largest upside, while falling fertility and price-sensitive patients will limit volume gains.

How the prenatal cfDNA screening estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines birth statistics, published test prices, Medicare fee and volume estimates, laboratory announcements and public guidance on RhD testing. Segment splits and state growth rates are Credence Research estimates, while state shares follow the split defined for this report. Sources used are government agencies, health regulators, official statistics, international agency data, peer-reviewed studies and company publications, and no interviews or surveys were used.

Funded RhD pathways and genome-wide screens carry growth

Australian noninvasive prenatal testing spending is expected to reach USD 136.9 million by 2035, a 7.74% CAGR during 2026–2035, as cell-free DNA screening becomes the default first-trimester choice and funded RhD testing reaches most RhD-negative women. New South Wales should keep the largest share, while the smaller states and territories grow fastest as public laboratories expand. Genome-wide options and single-gene analysis will add value per test. Laboratories that combine domestic processing, fast results and included genetic counseling should win the most referrals.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.